Published in J Clin Endocrinol Metab on July 05, 2005
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab (2008) 5.94
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer (2008) 3.04
Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A (2007) 1.84
Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res (2008) 0.95
Prognostic biomarkers in thyroid cancer. Virchows Arch (2014) 0.95
Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. Virchows Arch (2007) 0.92
OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. Br J Cancer (2007) 0.91
Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. Cancer Res Treat (2009) 0.89
Inflammation in thyroid oncogenesis. Am J Cancer Res (2012) 0.87
Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas. PLoS One (2010) 0.85
Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas. J Clin Endocrinol Metab (2012) 0.83
Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma. Front Endocrinol (Lausanne) (2012) 0.83
Expression of osteopontin in patients with thyroid dysfunction. PLoS One (2013) 0.79
CBX7 and HMGA1b proteins act in opposite way on the regulation of the SPP1 gene expression. Oncotarget (2015) 0.78
Osteopontin expression in papillary thyroid carcinoma and its relationship with the BRAF mutation and tumor characteristics. J Korean Surg Soc (2012) 0.77
The role of podoplanin in the biology of differentiated thyroid cancers. PLoS One (2014) 0.76
The pattern and significance of the calcifications of papillary thyroid microcarcinoma presented in preoperative neck ultrasonography. Ann Surg Treat Res (2014) 0.76
Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma. BMC Genomics (2015) 0.76
Characteristics of a thyroid carcinoma cell line derived from spinal metastasis. Biosci Rep (2016) 0.75
Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. Oncotarget (2016) 0.75
Correlation between calcification and bone sialoprotein and osteopontin in papillary thyroid carcinoma. Int J Clin Exp Pathol (2015) 0.75
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med (2002) 4.69
BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst (2006) 3.61
Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res (2005) 3.44
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab (2008) 3.38
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res (2002) 3.33
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab (2007) 2.74
Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res (2005) 2.10
Retracted The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest (2005) 2.09
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett (2004) 2.00
Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene (2002) 1.99
Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int J Cardiol (2013) 1.99
Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death. Circ Res (2006) 1.99
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab (2006) 1.98
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell (2006) 1.96
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.95
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab (2004) 1.82
New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab (2008) 1.76
Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg (2005) 1.75
Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem (2006) 1.72
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res (2007) 1.65
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene (2004) 1.63
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab (2010) 1.63
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab (2012) 1.62
Targeting the RET pathway in thyroid cancer. Clin Cancer Res (2009) 1.62
Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab (2009) 1.59
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.56
BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.52
Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab (2010) 1.50
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res (2007) 1.47
Surgical treatment of pleural recurrence from thymoma. Eur J Cardiothorac Surg (2008) 1.46
Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid (2012) 1.45
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol (2004) 1.43
BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res (2006) 1.43
Robo4 signaling in endothelial cells implies attraction guidance mechanisms. J Biol Chem (2006) 1.38
Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.38
Thyroid cancer and inflammation. Mol Cell Endocrinol (2009) 1.37
Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res (2005) 1.35
RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab (2007) 1.31
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol (2006) 1.29
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer (2010) 1.28
Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res (2008) 1.28
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer (2008) 1.26
Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res (2004) 1.25
Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology (2007) 1.19
Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis (2005) 1.18
The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab (2011) 1.18
Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci (2002) 1.17
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res (2007) 1.17
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood (2003) 1.17
Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene (2005) 1.16
The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.16